Table 1.
Comparison of pivotal phase III clinical trials with available results evaluating immune checkpoints inhibitors.
| Study Name | Tested Drugs | Comparison | Phase | Histology | Therapy Setting | OS (HR, 95% CI, p) |
Median PFS (HR, 95% CI) |
ORR (%) |
CR (%) |
Grade 3 (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Javelin Renal 101 | avelumab + axitinib | sunitinib | III | ccRCC | First line | 12-mo: 86% vs. 83% (0.78; 0.55–1.08; p = 0.14) |
13.8 vs. 7.2 mo (0.61) |
55.2 vs. 25,5 | 3.4 vs. 1.8 | 71.2 vs. 71.5 |
| Keynote 426 | pembrolizumab + axitinib | sunitinib | III | ccRCC | First line | 12-mo: 90% vs. 78% (0.53; 0.38–0.74; p < 0.0001) |
15.1 vs. 11.1 mo (0.69; 0.57–0.84) |
59.3 vs. 35.7 | 5.8 vs. 1.9 | 75.8 vs. 70.6 |
| CheckMate 214 | nivolumab + ipilimumab | sunitinib | III | ccRCC | First line | 30-mo : 60% vs, 47% (0.66; 0.54–0.80; p < 0.0001) |
11.6 vs. 8.4 mo (0.82; 0.64–1,05) |
42 vs. 29 | 9 vs. 1 | 47 vs. 64 |
| Immotion 151 | atezolizumab + bevacizumab | sunitinib | III | ccRCC | First line | 24 mo : 63% vs. 60% (0.93; 0.76–1.14; p = 0·4751) |
11.2 vs. 7.7 mo (0.74; 0.57–0.96) |
43 vs. 25 | 9 vs. 4 | 40 vs. 54 |
Abbreviations: OS = overall survival; HR = Hazard Ratio; PFS = progression-free survival; ORR = objective response rate; CR = complete response; ccRCC: clear cell renal cell carcinoma, mo = months.